Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
4.09
USD
|
-0.49%
|
|
+0.25%
|
-12.98%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
184.6
|
62.26
|
141.2
|
176.8
|
636.1
|
565.2
|
-
|
-
|
Enterprise Value (EV)
1 |
184.6
|
62.26
|
141.2
|
176.8
|
636.1
|
565.2
|
565.2
|
565.2
|
P/E ratio
|
-2.3
x
|
-1.37
x
|
-3.88
x
|
-6.2
x
|
-14.2
x
|
-10.2
x
|
-10
x
|
-48.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
242
x
|
-
|
-
|
-
|
-
|
115
x
|
11.3
x
|
EV / Revenue
|
-
|
242
x
|
-
|
-
|
-
|
-
|
115
x
|
11.3
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-4.08
x
|
-1.56
x
|
-3.5
x
|
-5.12
x
|
-12.4
x
|
-9.58
x
|
-6.5
x
|
-8.19
x
|
FCF Yield
|
-24.5%
|
-64.1%
|
-28.6%
|
-19.5%
|
-8.07%
|
-10.4%
|
-15.4%
|
-12.2%
|
Price to Book
|
2.24
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
41,210
|
54,141
|
113,869
|
114,044
|
135,341
|
138,189
|
-
|
-
|
Reference price
2 |
4.480
|
1.150
|
1.240
|
1.550
|
4.700
|
4.090
|
4.090
|
4.090
|
Announcement Date
|
3/12/20
|
3/10/21
|
3/30/22
|
3/30/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.257
|
-
|
-
|
-
|
-
|
4.904
|
50.21
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-52.17
|
-49.3
|
-41.48
|
-38.84
|
-60.01
|
-81.6
|
-70.58
|
-19.32
|
Operating Margin
|
-
|
-19,182.88%
|
-
|
-
|
-
|
-
|
-1,439.18%
|
-38.49%
|
Earnings before Tax (EBT)
1 |
-78.17
|
-49.62
|
-43.01
|
-38.15
|
-54.7
|
-74.45
|
-65.21
|
-15.87
|
Net income
1 |
-78.17
|
-49.62
|
-43.01
|
-38.15
|
-54.7
|
-78.02
|
-65.21
|
-15.87
|
Net margin
|
-
|
-19,305.45%
|
-
|
-
|
-
|
-
|
-1,329.63%
|
-31.62%
|
EPS
2 |
-1.950
|
-0.8400
|
-0.3200
|
-0.2500
|
-0.3300
|
-0.4000
|
-0.4086
|
-0.0850
|
Free Cash Flow
1 |
-45.27
|
-39.88
|
-40.37
|
-34.55
|
-51.36
|
-59
|
-87
|
-69
|
FCF margin
|
-
|
-15,518.68%
|
-
|
-
|
-
|
-
|
-1,773.94%
|
-137.43%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/10/21
|
3/30/22
|
3/30/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.64
|
-8.046
|
-9.383
|
-10.54
|
-10.88
|
-12.11
|
-12.22
|
-18.04
|
-17.63
|
-22.48
|
-21.54
|
-20.04
|
-19.19
|
-17.81
|
-17.67
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-11.31
|
-8.3
|
-9.164
|
-10.39
|
-10.3
|
-10.56
|
-11.44
|
-16.6
|
-16.1
|
-20.35
|
-19.87
|
-17.69
|
-16.33
|
-16.64
|
-16.13
|
Net income
1 |
-11.31
|
-8.3
|
-9.164
|
-10.39
|
-10.3
|
-10.56
|
-11.44
|
-16.6
|
-16.1
|
-20.35
|
-20.5
|
-19
|
-18.16
|
-16.64
|
-16.13
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0700
|
-0.0500
|
-0.0600
|
-0.0700
|
-0.0700
|
-0.0700
|
-0.0700
|
-0.1000
|
-0.0900
|
-0.1100
|
-0.1080
|
-0.0980
|
-0.0960
|
-0.0950
|
-0.0975
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
5/11/22
|
8/11/22
|
11/10/22
|
3/30/23
|
5/15/23
|
8/10/23
|
11/9/23
|
3/7/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-45.3
|
-39.9
|
-40.4
|
-34.6
|
-51.4
|
-59
|
-87
|
-69
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
2.000
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.15
|
0.05
|
0.06
|
0.01
|
0.3
|
0.52
|
0.52
|
0.52
|
Capex / Sales
|
-
|
18.29%
|
-
|
-
|
-
|
-
|
10.56%
|
1.04%
|
Announcement Date
|
3/12/20
|
3/10/21
|
3/30/22
|
3/30/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
4.09
USD Average target price
9
USD Spread / Average Target +120.05% Consensus |
1st Jan change
|
Capi.
|
---|
| -12.98% | 565M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|